Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Dresden, Germany.
Medical Faculty, Technical University Dresden, Dresden, Germany.
BJOG. 2021 Jul;128(8):1264-1272. doi: 10.1111/1471-0528.16635. Epub 2021 Jan 25.
Phaeochromocytoma and paraganglioma (PPGL) in pregnancy, if not diagnosed antepartum, pose a high risk for mother and child.
To examine the clinical clues of antepartum and postpartum/postmortem diagnosis of PPGL.
Case reports on PPGL in pregnancy published between 1 January 1988 and 30 June 2019 in English, German, Dutch or French.
Case reports containing a predefined minimum of clinical data on PPGL and pregnancy.
Two authors independently performed data extraction and assessed data quality. We calculated odds ratios (OR) (with 95% confidence intervals) and used uni- and multivariable logistic regression analysis.
Maternal and fetal/neonatal mortalities were 9.0% (18/200) and 14.2% (29/204), respectively. Maternal mortality was 42-fold higher with PPGL diagnosed postpartum/postmortem (17/58; 29.3%) than antepartum (1/142; 0.7%) (adjusted OR 45.9, 95% CI 5.67-370, P = 0.0003). Offspring mortality was 2.6-fold higher with PPGL diagnosed postpartum/postmortem than antepartum (OR 3.1, 95% CI 1.38-6.91, P = 0.0044). Hypertension at admission (OR 2.29, 95% CI 1.12-4.68, P = 0.022), sweating (OR 3.14, 95% CI 1.29-7.63, P = 0.014) and a history of PPGL, a known PPGL-associated gene mutation or adrenal mass (OR 8.87, 95% CI 1.89-41.64, P = 0.0056) were independent factors of antepartum diagnosis. Acute onset of symptoms (OR 8.49, 95% CI 3.52-20.5, P < 0.0001), initial diagnosis of pre-eclampsia (OR 6.34, 95% CI 2.60-15.5, P < 0.0001), admission for obstetric care (OR 10.71, 95% CI 2.70-42.45, P = 0.0007) and maternal tachycardia (OR 2.72, 95% CI 1.26-5.85, P = 0.011) were independent factors of postpartum diagnosis.
Several clinical clues can assist clinicians in considering an antenatal diagnosis of PPGL in pregnancy, thus potentially improving outcome.
Systematic review of 204 pregnant patients with phaeochromocytoma identified clinical clues for a timely antepartum diagnosis.
未在产前诊断的嗜铬细胞瘤和副神经节瘤(PPGL)会对母婴造成高风险。
探讨产前和产后/死后诊断 PPGL 的临床线索。
检索了 1988 年 1 月 1 日至 2019 年 6 月 30 日期间以英文、德文、荷兰文或法文发表的关于妊娠期间 PPGL 的病例报告。
包含 PPGL 和妊娠的预定义最小临床数据的病例报告。
两位作者独立进行数据提取并评估数据质量。我们计算了比值比(OR)(95%置信区间),并使用单变量和多变量逻辑回归分析。
母亲和胎儿/新生儿死亡率分别为 9.0%(18/200)和 14.2%(29/204)。产后/死后诊断的 PPGL 母亲死亡率比产前诊断(17/58;29.3%)高 42 倍(调整 OR 45.9,95%CI 5.67-370,P=0.0003)。产后/死后诊断的 PPGL 胎儿/新生儿死亡率比产前诊断高 2.6 倍(OR 3.1,95%CI 1.38-6.91,P=0.0044)。入院时高血压(OR 2.29,95%CI 1.12-4.68,P=0.022)、出汗(OR 3.14,95%CI 1.29-7.63,P=0.014)和 PPGL 病史、已知与 PPGL 相关的基因突变或肾上腺肿块(OR 8.87,95%CI 1.89-41.64,P=0.0056)是产前诊断的独立因素。症状急性发作(OR 8.49,95%CI 3.52-20.5,P<0.0001)、最初诊断为子痫前期(OR 6.34,95%CI 2.60-15.5,P<0.0001)、因产科护理入院(OR 10.71,95%CI 2.70-42.45,P=0.0007)和母亲心动过速(OR 2.72,95%CI 1.26-5.85,P=0.011)是产后诊断的独立因素。
一些临床线索可以帮助临床医生考虑在妊娠期间进行产前诊断 PPGL,从而有可能改善结局。
对 204 例患有嗜铬细胞瘤的孕妇进行的系统回顾确定了及时进行产前诊断的临床线索。